Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rockeby strikes deal with UK's Nucare:

This article was originally published in Clinica

Executive Summary

Australia-listed, Singapore-based diagnostics group Rockeby biomed is to see its CanDia5 rapid test for candida distributed in the UK over the next five years by Nucare, a Milton Keynes-based marketing and support organisation for independent chemists and pharmaceutical companies. Under the terms of the agreement, Nucare will have exclusive distribution rights to the test for the first two years, as well as licences to other diagnostic tests produced or sold by Rockeby in the future. The CanDia5, used to detect vulvovaginal candidiasis (vaginal thrush), was recently CE-marked for over-the-counter sales. This will allow NuCare to sell the test for home use, under its own label in pharmacies in both the UK and Ireland.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048241

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel